Your browser doesn't support javascript.
loading
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon, Richard; Maycock, Shanna; Jackson, Aimee; Fox, Sonia; Freeman, Sylvie; Craddock, Charles; Thomas, Catherine; Homer, Emma; Leahy, Jane; Mamwell, Anna; Potter, Nicola; Russell, Nigel; Wei, Andrew; Ommen, Hans Beier; Hemmaway, Claire; Knapper, Steve; Billingham, Lucinda.
Afiliación
  • Dillon R; Department of Medical and Molecular Genetics, King's College London, London, UK. richard.dillon@kcl.ac.uk.
  • Maycock S; Department of Clinical Haematology, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, UK. richard.dillon@kcl.ac.uk.
  • Jackson A; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Fox S; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Freeman S; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Craddock C; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Thomas C; Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Homer E; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Leahy J; Centre for Clinical Haematology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Mamwell A; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Potter N; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
  • Russell N; Blood Cancer UK, London, UK.
  • Wei A; Blood Cancer UK, London, UK.
  • Ommen HB; Department of Medical and Molecular Genetics, King's College London, London, UK.
  • Hemmaway C; School of Medicine, Clinical Sciences Building, The University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK.
  • Knapper S; Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne. VIC 3000, Australia.
  • Billingham L; Department of Hematology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus C, Denmark.
BMC Cancer ; 22(1): 1174, 2022 Nov 14.
Article en En | MEDLINE | ID: mdl-36376888
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido